HYD LLC. for Cancer Research and Drug Development was established in 1992 for the development and worldwide marketing of drugs and consumer products primarily for the prevention and treatment of various kinds of cancer, that utilize a novel proprietary procedure, deuterium depletion. Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and to influence other physiological processes offering a completely safe, non-invasive at the same time a highly effective treatment modality.
All research and development, including drug registration and other product development, based on deuterium depletion technology is exclusively managed, organised and financed by HYD LLC. Different applications of deuterium depletion are protected by international patents and patent applications in most of the developed countries.
In recent years HYD entered the international market, the professional reputation and international recognition of the patent-protected deuterium depletion technology continues to grow. Research has started in several foreign countries in academic institutions, universities and cancer centers.
HYD’s deuterium depleted products are being sold world-wide. HYD Ltd. appeared on the market with the first deuterium depleted drinking water product called Vitaqua in 1995.
In 1999, HYD LLC. completed the development and registration of its new veterinary drug, Vetera-DDW-25® A.U.V., for the treatment of households pets with tumors.
The new formulation of deuterium depleted drinking water called Preventa® was placed on the market in 2000.
The CEO of the Company, inventor and research biologist Gábor Somlyai, Ph.D., over the years has successfully built HYD LLC. from a small research organisation into a profitable business with an excellent portfolio of existing and prospective products. In 2002 HYD Ltd. was ranked at the 40th position of the first 500 fastest-growing technology companies at Deloitte & Touche European Technology Fast 500 Programme, in an annual ranking of the 500 fastest-growing technology companies across Europe, the Middle East and Africa. In 2003 HYD Ltd.’s Business Profile was broadcasted on EuroNews Channel simultaneously in English, French, German, Italian and Spanish.
Deuterium depletion technology is protected by international patents, HYD’s patents were awarded at Genius ’96 and Genius I. Investors’ Olimpic Games.
Preventa deuterium depleted drinking water won 1st Prize at New Foods Innovation Contest in 2005. The award was offered for the most innovative food product. The jury particularly stressed the importance of the research and deuterium depletion-based products in health promotion.
In October 2009, HYD LLC opened its first shop and advisory center in Budapest, Hungary.
2010 – 1st International Symposium on Deuterium Depletion was held on 13-14 May 2010 in Budapest, Hungary. At the symposium leading scientists from five countries (Hungary, Romania, USA, Russia, Iran) presented and discussed current advances in the research and various application of deuterium depletion.
2012 – The 2nd International Congress on Deuterium Depletion was held on 17-18 May 2012 in Budapest, Hungary. At the conference, scientists from seven countries (USA, France, China, Russia, Turkey, Romania, Hungary) presented their results on the research and practical applications of deuterium depletion.
2012 – Primus Capital closed a HUF 400 Million HUF investment in HYD Pharma Ltd. The investment is being used for validation of research results, and for implementation of a new human phase II clinical test.
2015 – The 3rd International Congress on Deuterium Depletion was held on 7-8 May 2015 in Budapest, Hungary. At the conference leading scientists from seven countries (USA, France, Spain, United Kingdom, Russia, Sweden, Hungary) presented and discussed current advances in the research and various application of deuterium depletion. The conference programme focused on the advances in the research and clinical application of deuterium depletion, its present and future role in anticancer research and oncotherapy, diabetes research and mental diseases.